A
$ Value
—
Shares
—
Price
$9.0M
Filed
Nov 10
Insider
Name
LIGAND PHARMACEUTICALS INC
Title
—
CIK
0000886163
Roles
Director
10% Owner
Transaction Details
Transaction Date
2025-11-06
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
—
Footnotes
On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person.
Filing Info
LIGAND PHARMACEUTICALS INC's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-12-17 | PTHS | D | — |
| 2025-12-17 | PTHS | A | — |
| 2025-11-06 | PTHS | A | — |
| 2025-07-01 | PTHS | C | $15.0M |
| 2025-07-01 | PTHS | C | $0 |
| 2025-07-01 | PTHS | J | — |
Other Insiders at PTHS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Greenleaf Peter | — | $17K | 2026-04-02 |
| Davis Todd C | — | — | 2025-07-02 |
|
Francis Knuettel II
CFO, Treas & Secty
|
— | — | 2025-07-02 |
| Pauls Matthew | — | $16K | 2026-04-02 |
| Friedberg Ezra M | — | $12K | 2026-04-02 |
|
Plesha Scott M.
CEO and President
|
— | — | 2025-07-02 |
| Malamut Richard | — | $12K | 2026-04-02 |
| Baxter Richard B | — | — | 2025-07-02 |
|
Rangarao Sai
Chief Commercial Officer
|
— | — | 2025-07-02 |